Citius Pharmaceuticals, Inc. Annual Deferred Income Tax Expense (Benefit) in USD from 2022 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Citius Pharmaceuticals, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2022 to 2024.
  • Citius Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was $264K, a 83.5% increase year-over-year.
  • Citius Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $576K, unchanged from 2023.
  • Citius Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $576K, unchanged from 2022.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.